The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $69.67

Today's change-0.71 -1.01%
Updated August 31 11:02 AM EDT. Delayed by at least 15 minutes.
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $69.67

Today's change-0.71 -1.01%
Updated August 31 11:02 AM EDT. Delayed by at least 15 minutes.

Charles River Laboratories International Inc down (U.S.)$0.71

Charles River Laboratories International Inc is lower today, dropping (U.S.)$0.71 or 1.01% to (U.S.)$69.67. Over the last five days, shares have gained 5.93% and 9.48% year to date. Shares have outperformed the S&P 500 by 19.43% during the last year.

Key company metrics

  • Open(U.S.) $70.37
  • Previous close(U.S.) $70.38
  • High(U.S.) $70.77
  • Low(U.S.) $69.30
  • Bid / Ask(U.S.) $69.61 / (U.S.) $69.73
  • YTD % change+9.48%
  • Volume49,843
  • Average volume (10-day)444,293
  • Average volume (1-month)413,017
  • Average volume (3-month)429,923
  • 52-week range(U.S.) $55.47 to (U.S.) $84.69
  • Beta1.43
  • Trailing P/E23.61×
  • P/E 1 year forward19.35×
  • Forward PEG2.04×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.95
Updated August 31 11:02 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+10.76%

Based on its net profit margin of 10.76%, Charles River Laboratories International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX1.28%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 27, 201506/27/2015Mar 28, 201503/28/2015Dec 27, 201412/27/2014Sep 27, 201409/27/2014
Revenue340320330328
Total other revenue--------
Total revenue340320330328
Gross profit133120120118
Total cost of revenue207201210209
Total operating expense284277289281
Selling / general / administrative71717064
Research & development--------
Depreciation / amortization6578
Interest expense (income), net operating--------
Unusual expense (income)1120
Other operating expenses, total--------
Operating income56434146
Interest income (expense), net non-operating-4-3-3-3
Gain (loss) on sale of assets--------
Other--------
Income before tax60324044
Income after tax49322932
Income tax, total1101212
Net income49322732
Total adjustments to net income--------
Net income before extra. items49322832
Minority interest-10-10
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items49322832
Inc. avail. to common incl. extra. items49322732
Diluted net income49322732
Dilution adjustment--000
Diluted weighted average shares48484847
Diluted EPS excluding extraordinary itemsvalue per share1.020.660.590.68
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share1.030.681.250.69